Patents by Inventor Maria Emilia Di Francesco

Maria Emilia Di Francesco has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GLS1 inhibitors for treating disease
    Patent number: 10766892
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Grant
    Filed: May 14, 2019
    Date of Patent: September 8, 2020
    Assignee: Board of Regents, The University of Texas System
    Inventors: Maria Emilia Di Francesco, Philip Jones, Timothy Heffernan, Matthew M. Hamilton, Zhijun Kang, Michael J. Soth, Jason P. Burke, Kang Le, Christopher Lawrence Carroll, Wylie S. Palmer, Richard Lewis, Timothy McAfoos, Barbara Czako, Gang Liu, Jay Theroff, Zachary Herrera, Anne Yau
  • Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase
    Patent number: 10745420
    Abstract: The present invention relates to tetrahydropyrido[4,3-d]pyrimidine based compounds and methods which may be useful as inhibitors of ATR kinase for the treatment or prevention of cancer.
    Type: Grant
    Filed: August 13, 2019
    Date of Patent: August 18, 2020
    Assignees: Board of Regents, The University of Texas System, ChemPartner Corporation
    Inventors: Maria Emilia Di Francesco, Philip Jones, Christopher Lawrence Carroll, Jason Bryant Cross, Michael Garrett Johnson, Sarah Lively
  • SALTS OF HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE
    Publication number: 20200171017
    Abstract: The present disclosure relates to salts of heterocyclic compounds and methods that inhibit HIF pathway activity. The compounds are designed to treat or prevent cancer and other hypoxia-mediated diseases.
    Type: Application
    Filed: June 24, 2019
    Publication date: June 4, 2020
    Inventors: Philip JONES, Maria Emilia DI FRANCESCO, Timothy MCAFOOS
  • HETEROCYCLIC INHIBITORS OF ATR KINASE
    Publication number: 20200102296
    Abstract: The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of ATR kinase for the treatment or prevention of cancer.
    Type: Application
    Filed: July 10, 2019
    Publication date: April 2, 2020
    Inventors: Maria Emilia DI FRANCESCO, Philip JONES, Christopher Lawrence CARROLL, Jason Bryant CROSS, Suyambu Kesava Vijayan RAMASWAMY, Michael Garrett JOHNSON, Sarah LIVELY, David LAPOINTE
  • TETRAHYDROPYRIDO[4,3-d]PYRIMIDINE INHIBITORS OF ATR KINASE
    Publication number: 20190367536
    Abstract: The present invention relates to tetrahydropyrido[4,3-d]pyrimidine based compounds and methods which may be useful as inhibitors of ATR kinase for the treatment or prevention of cancer.
    Type: Application
    Filed: August 13, 2019
    Publication date: December 5, 2019
    Inventors: Maria Emilia DI FRANCESCO, Philip JONES, Christopher Lawrence CARROLL, Jason Bryant CROSS, Michael Garrett JOHNSON, Sarah LIVELY
  • CYCLIC DINUCLEOTIDES AS AGONISTS OF STIMULATOR OF INTERFERON GENE DEPENDENT SIGNALLING
    Publication number: 20190358254
    Abstract: Disclosed herein are new cyclic dinucleotide compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of modulation of immune response to disease, and induce Stimulator of Interferon Genes (STING) dependent type I interferon production and co-regulated genes in a human or animal subject are also provided for the treatment diseases such as cancer, particularly metastatic solid tumors and lymphomas, inflammation, allergic and autoimmune disease, infectious disease, and for use as anti-viral agents and vaccine adjuvants.
    Type: Application
    Filed: February 21, 2018
    Publication date: November 28, 2019
    Inventors: Maria Emilia DI FRANCESCO, Philip JONES, Michael A. CURRAN
  • Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase
    Patent number: 10421765
    Abstract: The present invention relates to tetrahydropyrido[4,3-d]pyrimidine based compounds and methods which may be useful as inhibitors of ATR kinase for the treatment or prevention of cancer.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: September 24, 2019
    Assignees: Board of Regents, The University of Texas System, ChemPartner Corporation
    Inventors: Maria Emilia Di Francesco, Philip Jones, Christopher Lawrence Carroll, Jason Bryant Cross, Michael Garrett Johnson, Sarah Lively
  • HETEROCYCLIC INHIBITORS OF ATR KINASE
    Publication number: 20190282584
    Abstract: The present disclosure relates to heterocyclic compounds and methods which inhibit ATR kinase to treat or prevent cancer.
    Type: Application
    Filed: March 18, 2019
    Publication date: September 19, 2019
    Inventors: Maria Emilia DI FRANCESCO, Philip JONES, Christopher Lawrence CARROLL, Suyambu Kesava Vijayan RAMASWAMY, Zhijun KANG, Michael Garrett JOHNSON, Sarah LIVELY, David LAPOINTE
  • ETHANEDIAMINE-HETEROCYCLE DERIVATIVES AS INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASES
    Publication number: 20190270739
    Abstract: The present invention relates to ethanediamine-heterocycle compounds that are able to act as inhibitors of PRMTs (protein arginine methyltransferases) for treating cancer and other diseases mediated by PRMTs.
    Type: Application
    Filed: March 1, 2019
    Publication date: September 5, 2019
    Inventors: Maria Emilia DI FRANCESCO, Philip JONES, Timothy Joseph MCAFOOS
  • HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE
    Publication number: 20190270753
    Abstract: The present invention relates to compounds and methods which may be useful as inhibitors of HIF pathway activity for the treatment or prevention of cancer and other hypoxia-mediated diseases.
    Type: Application
    Filed: December 21, 2018
    Publication date: September 5, 2019
    Inventors: Philip JONES, Maria Emilia DI FRANCESCO, Alessia PETROCCHI, Christopher L. CARROLL, Joe MARSZALEK, Barbara CZAKO, Ryan JOHNSON, Jay THEROFF
  • GLS1 INHIBITORS FOR TREATING DISEASE
    Publication number: 20190270736
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Application
    Filed: May 14, 2019
    Publication date: September 5, 2019
    Inventors: Maria Emilia DI FRANCESCO, Philip JONES, Timothy HEFFERNAN, Matthew M. HAMILTON, Zhijun KANG, Michael J. SOTH, Jason P. BURKE, Kang LE, Christopher Lawrence CARROLL, Wylie S. PALMER, Richard LEWIS, Timothy MCAFOOS, Barbara CZAKO, Gang LIU, Jay THEROFF, Zachary HERRERA, Anne YAU
  • Heterocyclic inhibitors of ATR kinase
    Patent number: 10392376
    Abstract: The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of ATR kinase for the treatment or prevention of cancer.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: August 27, 2019
    Assignees: Board of Regents, The University of Texas System, ChemPartner Corporation
    Inventors: Maria Emilia Di Francesco, Philip Jones, Christopher Lawrence Carroll, Jason Bryant Cross, Suyambu Kesava Vijayan Ramaswamy, Michael Garrett Johnson, Sarah Lively, David Lapointe
  • Salts of heterocyclic modulators of HIF activity for treatment of disease
    Patent number: 10363248
    Abstract: The present disclosure relates to salts of heterocyclic compounds and methods that inhibit HIF pathway activity. The compounds are designed to treat or prevent cancer and other hypoxia-mediated diseases.
    Type: Grant
    Filed: April 20, 2017
    Date of Patent: July 30, 2019
    Assignee: Board of Regents, The University of Texas System
    Inventors: Philip Jones, Maria Emilia Di Francesco, Timothy McAfoos
  • GLS1 inhibitors for treating disease
    Patent number: 10344025
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: July 9, 2019
    Assignee: Board of Regents, The University of Texas System
    Inventors: Maria Emilia Di Francesco, Philip Jones, Timothy Heffernan, Matthew M. Hamilton, Zhijun Kang, Michael J. Soth, Jason P. Burke, Kang Le, Christopher Lawrence Carroll, Wylie S. Palmer, Richard Lewis, Timothy McAfoos, Barbara Czako, Gang Liu, Jay Theroff, Zachary Herrera, Anne Yau
  • GLUTAMINASE INHIBITOR THERAPY
    Publication number: 20190134032
    Abstract: Disclosed herein are methods of treating a subject having an altered NRF2/KEAP1 pathway, and compounds and compositions useful in such treatment. Also disclosed herein are methods of evaluating whether to administer a compound that inhibits glutathione production or a glutaminase inhibitor to a subject.
    Type: Application
    Filed: August 22, 2018
    Publication date: May 9, 2019
    Inventors: Timothy P. HEFFERNAN, Carlo TONIATTI, Jeffrey KOVACS, Virginia GIULIANI, Nakia SPENCER, Maria Emilia DI FRANCESCO, Christopher A. BRISTOW
  • HETEROCYCLIC INHIBITORS OF KDM5 FOR THE TREATMENT OF DISEASE
    Publication number: 20190135793
    Abstract: The present invention relates to compounds and methods useful as inhibitors of KDM5 for the treatment or prevention of cancer.
    Type: Application
    Filed: May 17, 2018
    Publication date: May 9, 2019
    Inventors: Alessia PETROCCHI, Maria Emilia DI FRANCESCO, Philip JONES, Richard Thomas LEWIS, Naphtali REYNA, Matthew HAMILTON, Michelle HAN
  • HETEROCYCLIC INHIBITORS OF ATR KINASE
    Publication number: 20190055240
    Abstract: The present invention relates to heterocyclic compounds and methods which may be useful as inhibitors of ATR kinase for the treatment or prevention of cancer.
    Type: Application
    Filed: August 17, 2018
    Publication date: February 21, 2019
    Inventors: Maria Emilia DI FRANCESCO, Philip JONES, Christopher Lawrence CARROLL, Jason Bryant CROSS, Zhijun KANG, Michael Garrett JOHNSON, Sarah LIVELY
  • Heterocyclic modulators of HIF activity for treatment of disease
    Patent number: 10208059
    Abstract: The present invention relates to compounds and methods which may be useful as inhibitors of HIF pathway activity for the treatment or prevention of cancer and other hypoxia-mediated diseases.
    Type: Grant
    Filed: October 4, 2016
    Date of Patent: February 19, 2019
    Assignee: Board of Regents, The University of Texas System
    Inventors: Philip Jones, Maria Emilia Di Francesco, Alessia Petrocchi, Christopher L. Carroll, Joe Marszalek, Barbara Czako, Ryan Johnson, Jay Theroff
  • HETEROCYCLIC INHIBITORS OF ATR KINASE
    Publication number: 20190016713
    Abstract: The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of ATR kinase for the treatment or prevention of cancer.
    Type: Application
    Filed: July 13, 2018
    Publication date: January 17, 2019
    Inventors: Maria Emilia DI FRANCESCO, Philip JONES, Christopher Lawrence CARROLL, Jason Bryant CROSS, Suyambu Kesava Vijayan RAMASWAMY, Michael Garrett JOHNSON, Sarah LIVELY, David LAPOINTE
  • TETRAHYDROPYRIDO[4,3-d]PYRIMIDINE INHIBITORS OF ATR KINASE
    Publication number: 20180370990
    Abstract: The present invention relates to tetrahydropyrido[4,3-d]pyrimidine based compounds and methods which may be useful as inhibitors of ATR kinase for the treatment or prevention of cancer.
    Type: Application
    Filed: May 25, 2018
    Publication date: December 27, 2018
    Inventors: Maria Emilia DI FRANCESCO, Philip JONES, Christopher Lawrence CARROLL, Jason Bryant CROSS, Michael Garrett JOHNSON, Sarah LIVELY